Peakdale Molecular is introducing a new range of Peakexplorer screening libraries with the first library focused on G-Protein Coupled Receptors (GPCR).
Peakdale Molecular is introducing a new range of Peakexplorer screening libraries with the first library focused on G-Protein Coupled Receptors (GPCR).
This library of over 1000 well-characterised highly diverse and novel drug-like compounds has been created using a combination of state-of-the-art in silico design and Peakdale's proprietary chemistry.
It is now available and ready to be formatted for screening by pharmaceutical and biotech customers.
GPCRs are associated with many diseases and are therefore important targets for screening new drugs.
Peakdale is renowned for its innovative chemistry; and the design, creation and successful synthesis of novel chemotypes that have proven to be highly successful in pharmaceutical research.
The Company has partnered its unique chemistry expertise and novel intermediates collection with De Novo Pharmaceuticals' in silico technologies to design highly focused libraries of novel, drug-like compounds to broaden the exploration of GPCR-relevant chemical space.
Kimberley Morrison, CEO of Peakdale Molecular, said, "Peakdale has spent many years building a track record in creating novel, drug-like lead compounds for client-specified biological targets.
"Many of these compounds are now showing great promise in clinical trials. "We are very excited that, through our collaboration with De Novo, we can now provide our clients with a set of over 1000 novel compounds to aid their GPCR drug discovery".
Dr Gareth Jenkins, Peakdale's Business Development Manager added, "Following the launch of this library we plan to introduce at least two additional Peakexplorer GPCR libraries this year, allowing our clients ready, novel access to even more GPCR-relevant chemical-space."
